{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:04:19Z","timestamp":1778029459777,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ningxia Natural Science Foundation","award":["No. 2021AAC03354"],"award-info":[{"award-number":["No. 2021AAC03354"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to investigate the role of FAM172A in epithelial ovarian cancer (EOC), a highly lethal gynecological malignancy often diagnosed at late stages with limited treatment options. FAM172A expression was evaluated in EOC and normal ovarian tissues using western blotting and immunohistochemistry, and its association with patient prognosis, treatment response, and CA125 levels was assessed by multivariate regression analysis. Functional assays were performed to examine the effects of FAM172A on EOC cell proliferation, migration, and invasion. In vivo models were used to evaluate the influence of FAM172A on tumor growth, metastasis, and chemosensitivity. The underlying mechanism was explored by modulating the PI3K-Akt pathway with pharmacological inhibitors and activators. FAM172A was significantly upregulated in EOC tissues, and its elevated expression correlated with poor prognosis, chemotherapy resistance, and increased CA125 levels. Multivariate analysis identified FAM172A expression, platinum sensitivity, and CA125 as independent prognostic factors. In vitro, FAM172A promoted malignant behavior and conferred resistance to cisplatin. In vivo, knockdown of FAM172A suppressed tumor progression and enhanced the efficacy of cisplatin. Mechanistically, FAM172A exerted its effects through regulation of the PI3K-Akt pathway, and modulation of PI3K signaling rescued FAM172A-induced phenotypic changes. These findings highlight FAM172A as a critical promoter of EOC progression, associated with aggressive tumor characteristics and treatment failure. By activating the PI3K-Akt pathway, FAM172A represents a promising therapeutic target for EOC, potentially offering new strategies to improve patient outcomes, particularly in overcoming chemoresistance.<\/jats:p>","DOI":"10.1038\/s41598-025-26676-9","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:03:21Z","timestamp":1764777801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FAM172A promotes epithelial ovarian cancer progression and induces platinum resistance via the PI3K\/AKT pathway"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuanyuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanru","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"26676_CR1","doi-asserted-by":"crossref","unstructured":"Chiappa, M. et al. Brca1Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Proficient and Deficient Murine Ovarian Cells. Cancers. 14 (2022).","DOI":"10.3390\/cancers14071807"},{"key":"26676_CR2","doi-asserted-by":"publisher","first-page":"646135","DOI":"10.3389\/fonc.2021.646135","volume":"11","author":"M He","year":"2021","unstructured":"He, M., Lai, Y., Peng, H. & Tong, C. Role of lymphadenectomy during interval debulking surgery performed after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Front. Oncol. 11, 646135 (2021).","journal-title":"Front. Oncol."},{"key":"26676_CR3","doi-asserted-by":"crossref","unstructured":"Rabelo-Fern\u00e1ndez, R. J. et al. Reduced RBPMS levels promote cell proliferation and decrease cisplatin sensitivity in ovarian cancer cells. Int J. Mol. Sci 23, 535 (2022).","DOI":"10.3390\/ijms23010535"},{"key":"26676_CR4","doi-asserted-by":"crossref","unstructured":"Hwangbo, S. et al. Development of machine learning models to predict platinum sensitivity of High-Grade serous ovarian carcinoma. Cancers (Basel). 13,  1875 (2021).","DOI":"10.3390\/cancers13081875"},{"key":"26676_CR5","doi-asserted-by":"crossref","unstructured":"Fumet, J. D. et al. Genomic instability is defined by specific tumor microenvironment in ovarian cancer: A subgroup analysis of AGO OVAR 12 trial. Cancers (Basel). 14, 1189 (2022).","DOI":"10.3390\/cancers14051189"},{"key":"26676_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13048-023-01180-8","volume":"16","author":"R Miyakawa","year":"2023","unstructured":"Miyakawa, R. et al. SPON1 is an independent prognostic biomarker for ovarian cancer. J. Ovarian Res. 16, 95 (2023).","journal-title":"J. Ovarian Res."},{"key":"26676_CR7","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","volume":"21","author":"RP Rocconi","year":"2020","unstructured":"Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 21, 1661\u20131672 (2020).","journal-title":"Lancet Oncol."},{"key":"26676_CR8","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3892\/ol.2017.6585","volume":"14","author":"W Liu","year":"2017","unstructured":"Liu, W. et al. Expression of family with sequence similarity 172 member A and nucleotide-binding protein 1 is associated with the poor prognosis of colorectal carcinoma. Oncol. Lett. 14, 3587\u20133593 (2017).","journal-title":"Oncol. Lett."},{"key":"26676_CR9","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1073\/pnas.1715378115","volume":"115","author":"C B\u00e9langer","year":"2018","unstructured":"B\u00e9langer, C. et al. Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome. Proc. Natl. Acad. Sci. U.S.A. 115, E620\u2013E629 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"26676_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-20-0181","volume":"27","author":"P Xu","year":"2020","unstructured":"Xu, P. et al. FAM172A promotes follicular thyroid carcinogenesis and May be a marker of FTC. Endocr. Relat. Cancer. 27, 657\u2013669 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"26676_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/mmr.2015.4548","volume":"13","author":"M Li","year":"2016","unstructured":"Li, M. et al. FAM172A protein promotes the proliferation of human papillary thyroid carcinoma cells via the p38 mitogen-activated protein kinase pathway. Mol. Med. Rep. 13, 353\u2013358 (2016).","journal-title":"Mol. Med. Rep."},{"key":"26676_CR12","doi-asserted-by":"crossref","unstructured":"Xu, W. et al. FAM171A2 The gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases. Science Advances. 6, eabb3063 (2020).","DOI":"10.1126\/sciadv.abb3063"},{"key":"26676_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13148-023-01553-2","volume":"15","author":"M Larsen","year":"2023","unstructured":"Larsen, M. et al. Objective and subjective measures of sleep initiation are differentially associated with DNA methylation in adolescents. Clin. Epigenetics. 15, 136 (2023).","journal-title":"Clin. Epigenetics"},{"key":"26676_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41398-022-02236-x","volume":"12","author":"L Guo","year":"2022","unstructured":"Guo, L. et al. Epigenome-wide DNA methylation analysis of whole blood cells derived from patients with GAD and OCD in the Chinese Han population. Translational Psychiatry. 12, 465 (2022).","journal-title":"Translational Psychiatry"},{"key":"26676_CR15","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.21037\/tcr-20-2868","volume":"9","author":"AM Xu","year":"2020","unstructured":"Xu, A. M., He, C. J., Tuerxun, Z. & Anikezi, A. FAM172A affects cell proliferation and apoptosis not by targeting \u03b2-tubulin in HepG2 cells. Transl Cancer Res. 9, 5637\u20135644 (2020).","journal-title":"Transl Cancer Res."},{"key":"26676_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-20-0181","volume":"27","author":"PP Xu","year":"2020","unstructured":"Xu, P. P. et al. FAM172A promotes follicular thyroid carcinogenesis and May be a marker of FTC. Endocr. Relat. Cancer. 27, 657\u2013669 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"26676_CR17","doi-asserted-by":"crossref","unstructured":"Liu, W. et al. [Corrigendum] miR\u201327a promotes proliferation, migration, and invasion of colorectal cancer by targeting FAM172A and acts as a diagnostic and prognostic biomarker. Oncol Rep. 51, 83 (2024).","DOI":"10.3892\/or.2024.8742"},{"key":"26676_CR18","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling. Biol Open. 9, bio048462 (2020).","DOI":"10.1242\/bio.048462"},{"key":"26676_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2021.08.023","volume":"333","author":"M Chen","year":"2021","unstructured":"Chen, M. et al. Deletion of Fam172a accelerates advanced atherosclerosis and induces plaque instability. Atherosclerosis 333, 39\u201347 (2021).","journal-title":"Atherosclerosis"},{"key":"26676_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41419-020-2655-1","volume":"11","author":"M Zha","year":"2020","unstructured":"Zha, M. et al. The circadian clock gene Bmal1 facilitates cisplatin-induced renal injury and hepatization. Cell. Death Dis. 11, 446 (2020).","journal-title":"Cell. Death Dis."},{"key":"26676_CR21","doi-asserted-by":"publisher","first-page":"3461251","DOI":"10.1155\/2019\/3461251","volume":"2019","author":"A Salatino","year":"2019","unstructured":"Salatino, A. et al. H-Ferritin affects Cisplatin-Induced cytotoxicity in ovarian cancer cells through the modulation of ROS. Oxid. Med. Cell. Longev. 2019, 3461251 (2019).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"26676_CR22","doi-asserted-by":"crossref","unstructured":"Cheng, M. et al. The mitochondrial PHB2\/OMA1\/DELE1 pathway cooperates with Endoplasmic reticulum stress to facilitate the response to chemotherapeutics in ovarian cancer. Int J. Mol. Sci. 23, 1320 (2022).","DOI":"10.3390\/ijms23031320"},{"key":"26676_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molonc.2016.01.003","volume":"10","author":"A Kulshrestha","year":"2016","unstructured":"Kulshrestha, A. et al. Selective Inhibition of tumor cell associated Vacuolar-ATPase \u2018a2\u2019 isoform overcomes cisplatin resistance in ovarian cancer cells. Mol. Oncol. 10, 789\u2013805 (2016).","journal-title":"Mol. Oncol."},{"key":"26676_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/15384047.2017.1345391","volume":"18","author":"F Zhang","year":"2017","unstructured":"Zhang, F. et al. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. Cancer Biol. Ther. 18, 606\u2013615 (2017).","journal-title":"Cancer Biol. Ther."},{"key":"26676_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0002-9149(88)90780-1","volume":"61","author":"V Fuster","year":"1988","unstructured":"Fuster, V., Cohen, M. & Chesebro, J. H. Usefulness of aspirin for coronary artery disease. Am. J. Cardiol. 61, 637\u2013640 (1988).","journal-title":"Am. J. Cardiol."},{"key":"26676_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ygyno.2005.02.006","volume":"98","author":"JA Smith","year":"2005","unstructured":"Smith, J. A., Ngo, H., Martin, M. C. & Wolf, J. K. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol. Oncol. 98, 141\u2013145 (2005).","journal-title":"Gynecol. Oncol."},{"key":"26676_CR27","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1038\/s41467-021-26758-y","volume":"12","author":"JPJ Hall","year":"2021","unstructured":"Hall, J. P. J. Is the bacterial chromosome a mobile genetic element? Nat. Commun. 12, 6400 (2021).","journal-title":"Nat. Commun."},{"key":"26676_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1530\/ERC-20-0436","volume":"28","author":"MD Aydemirli","year":"2021","unstructured":"Aydemirli, M. D. et al. Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. Endocr. Relat. Cancer. 28, 377\u2013389 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"26676_CR29","doi-asserted-by":"crossref","unstructured":"Antonino G, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 22, 138 (2023).","DOI":"10.1186\/s12943-023-01827-6"},{"key":"26676_CR30","doi-asserted-by":"crossref","unstructured":"Zhao, H. et al. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. Analytical cellular pathology (Amsterdam). 5901083 (2019).\u00a0","DOI":"10.1155\/2019\/5901083"},{"key":"26676_CR31","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1038\/s41598-024-53854-y","volume":"14","author":"S Ma","year":"2024","unstructured":"Ma, S. et al. HIF-2\u03b1-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K\/Akt pathway to inhibit apoptosis and facilitate DNA repair process. Sci. Rep. 14, 3870 (2024).","journal-title":"Sci. Rep."},{"key":"26676_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.freeradbiomed.2024.02.004","volume":"214","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. \u03b2-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN\/PI3K\/AKT signaling pathway in ovarian cancer. Free Radic. Biol. Med. 214, 137\u2013157 (2024).","journal-title":"Free Radic. Biol. Med."},{"key":"26676_CR33","doi-asserted-by":"crossref","unstructured":"Parashar, D. et al. Patient-Derived ovarian cancer spheroids rely on PI3K-AKT signaling addiction for cancer stemness and chemoresistance. Cancers (Basel). 14, 958 (2022).","DOI":"10.3390\/cancers14040958"},{"key":"26676_CR34","doi-asserted-by":"publisher","first-page":"977660","DOI":"10.3389\/fphar.2022.977660","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Current landscape of personalized clinical treatments for triple-negative breast cancer. Front. Pharmacol. 13, 977660 (2022).","journal-title":"Front. Pharmacol."},{"key":"26676_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2174\/1570161115666170105124038","volume":"15","author":"KS Siveen","year":"2017","unstructured":"Siveen, K. S. et al. Vascular endothelial growth factor (VEGF) signaling in tumour vascularization: potential and challenges. Curr. Vasc Pharmacol. 15, 339\u2013351 (2017).","journal-title":"Curr. Vasc Pharmacol."},{"key":"26676_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.actbio.2022.03.021","volume":"143","author":"H Niu","year":"2022","unstructured":"Niu, H., Gao, N., Dang, Y., Guan, Y. & Guan, J. Delivery of VEGF and delta-like 4 to synergistically regenerate capillaries and arterioles in ischemic limbs. Acta Biomater. 143, 295\u2013309 (2022).","journal-title":"Acta Biomater."},{"key":"26676_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1620\/tjem.241.239","volume":"241","author":"M Ma","year":"2017","unstructured":"Ma, M. & Yu, N. Over-Expression of TBL1XR1 indicates poor prognosis of serous epithelial ovarian cancer. Tohoku J. Exp. Med. 241, 239\u2013247 (2017).","journal-title":"Tohoku J. Exp. Med."},{"key":"26676_CR38","doi-asserted-by":"crossref","unstructured":"Yuwei S, et al. Exosomal miR-301a-3p from esophageal squamous cell carcinoma cells promotes angiogenesis by inducing M2 polarization of macrophages via the PTEN\/PI3K\/AKT signaling pathway. Cancer Cell Int. 22, 153 (2022).","DOI":"10.1186\/s12935-022-02570-6"},{"key":"26676_CR39","doi-asserted-by":"crossref","unstructured":"Danxue H, Liyuan K, Hongxia C, Su L, Feilong SJBWH. Efficacy and safety of VEGF\/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Womens Health. 24, 34 (2024).","DOI":"10.1186\/s12905-023-02879-y"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26676-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26676-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:16:38Z","timestamp":1764857798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26676-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26676"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26676-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures complied with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. This study was approved by the Ethics Committee of the General Hospital of Ningxia Medical University (Approval No. 2021112). Written informed consent for specimen use was obtained from all patients prior to surgery. All methods were performed in accordance with relevant guidelines and regulations.All animal procedures were conducted in accordance with relevant guidelines, and all methods received approval from the Animal Ethics Committee of the Ningxia Medical University Experimental Animal Center (Approval No. IACUC-NYLAC-2023-124). The methods are reported following the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"43128"}}